Pavmed INC Schedule 13G passive stakes

David S. Nagelberg and the David S. Nagelberg 2003 Revocable Trust have increased their beneficial ownership of PAVmed Inc. common stock to 8.8% and 5.9% respectively.

Two Seas Capital LP and affiliates have reported a 9.99% beneficial ownership stake in PAVmed Inc. common stock.

First Manhattan Co. LLC, FMC Group Holdings LP, and First Manhattan Management LLC collectively report beneficial ownership of 9.6% of PAVmed Inc.'s common stock as of March 31, 2026.

Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri have filed a Schedule 13G reporting a 9.99% beneficial ownership stake in PAVmed Inc.

Tasso Partners, LLC and Dana Carrera report combined beneficial ownership of 15.3% of PAVmed Inc. common stock as of March 27, 2026.

Scopia Holdings LLC and Matthew Sirovich report beneficial ownership of 9.9% of PAVmed Inc. common stock, totaling 637,670 shares.

David S. Nagelberg and the David S. Nagelberg 2003 Revocable Trust have jointly filed a Schedule 13G, disclosing beneficial ownership of 8.6% of PAVmed Inc.'s common stock.

Scott V. Dols has reported beneficial ownership of 346,155 shares, representing 5.4% of PAVmed Inc.'s outstanding common stock, as of March 27, 2026.

Craig Kallman and the Craig Kallman 2015 Living Trust jointly report beneficial ownership of 6.0% of PAVmed Inc. common stock.

Tasso Partners, LLC and Dana Carrera have amended their Schedule 13G filing to report a combined beneficial ownership of 14.3% of PAVmed Inc.'s common stock, totaling 914,246 shares.

Sargent Investment Group, LLC has reported a beneficial ownership of 5.79% in PAVmed Inc.'s common stock, totaling 1,006,300 shares.

First Manhattan Co. LLC has filed an amended Schedule 13G, reporting a 4.25% beneficial ownership stake in PAVmed Inc.'s common stock as of March 31, 2025.

Tasso Partners, LLC and Dana Carrera have jointly reported a beneficial ownership of 18.9% in PAVmed Inc.'s common stock, totaling 2,574,350 shares, as a passive investment.

Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri have disclosed a combined 9.9% beneficial ownership stake in PAVMED INC., comprising common stock and convertible notes.